Latest Conference Articles

Stay up to date on the latest oncology and nursing conferences.

Balstilimab Zalifrelimab Combination Yields Promising Results in Recurrent/Metastatic Cervical Cancer

Balstilimab Zalifrelimab Combination Yields Promising Results in Recurrent/Metastatic Cervical Cancer

September 23rd 2021, 3:00pm

A phase 2 trial presented at the 2021 ESMO Annual Congress showed that Balstilimab plus Zalifrelimab induced superior response rates, duration of responses, and overall survival in patients with recurrent/metastatic cervical cancer.

Anticipating the Future of Polycythemia Vera Treatment: Weighing Efficacy and Toxicity

Anticipating the Future of Polycythemia Vera Treatment: Weighing Efficacy and Toxicity

September 22nd 2021, 6:00pm

An expert presenting at the Society of Hematology Oncology 2021 Annual Conference shared important updates in polycythemia vera (PV) treatment and weighed in on the direction of future treatment.

Pembrolizumab in Addition to Chemo Holds Potential as New SOC in Cervical Cancer Frontline Setting

Pembrolizumab in Addition to Chemo Holds Potential as New SOC in Cervical Cancer Frontline Setting

September 22nd 2021, 2:00pm

Data presented at the 2021 ESMO Congress suggest that pembrolizumab in addition to chemo with or without bevacizumab may become new standard of care in the frontline setting of cervical cancer treatment.

Higher BMI Linked to Superior Survival in mCRPC

Higher BMI Linked to Superior Survival in mCRPC

September 20th 2021, 6:00pm

Obese men are more likely to have improved overall survival following treatment for mCRPC than man who are overweight or normal weight, analysis finds.

Tisotumab Vedotin Combinations May Be Associated with Meaningful Responses in Recurrent/Metastatic Cervical Cancer

Tisotumab Vedotin Combinations May Be Associated with Meaningful Responses in Recurrent/Metastatic Cervical Cancer

September 20th 2021, 2:00pm

Interim findings presented at the 2021 ESMO congress suggest that tisotumab vedotin plus frontline carboplatin and second-/third-Line pembrolizumab may be a suitable treatment option for recurrent/metastatic cervical cancer.

Study Finds Similar Clinical Characteristics in VHL-Mutated and VHL Wild Type Clear Cell RCC

Study Finds Similar Clinical Characteristics in VHL-Mutated and VHL Wild Type Clear Cell RCC

September 18th 2021, 6:00pm

Characteristics such as low positive PD-L1 expression and rare high positive staining were identified in both patients with VHL-mutated and VHL wild type clear cell renal cell carcinoma.

Dostarlimab Elicits Superior Responses in Patients with High Mutational Burden in Endometrial Cancer

Dostarlimab Elicits Superior Responses in Patients with High Mutational Burden in Endometrial Cancer

September 17th 2021, 6:00pm

Patients with endometrial cancer and high tumor mutational burden experienced superior overall response rates to the agent dostarlimab than patients with low mutational burden.

Addition of Darolutamide to ADT Shows Comparable Safety Profile Among Patients With nmCRPC

Addition of Darolutamide to ADT Shows Comparable Safety Profile Among Patients With nmCRPC

September 16th 2021, 6:00pm

Patients with nonmetastatic castration-resistant prostate cancer often undergo prolonged treatment periods, making the safety profile of therapies like darolutamide an important factor in optimum treatment selection.

Yoga Encourages Antitumor Response, Boosts Quality of Life in Patients with Prostate Cancer

Yoga Encourages Antitumor Response, Boosts Quality of Life in Patients with Prostate Cancer

September 16th 2021, 2:00pm

Yoga has a positive impact on the vagus nerve, which influences how people think, remember, and feel, and therefore can improve the mental well-being of patients with prostate cancer.

Cilta-cel CAR T-Cell Therapy May Satisfy Need For Deeper Treatment Responses in Multiple Myeloma

Cilta-cel CAR T-Cell Therapy May Satisfy Need For Deeper Treatment Responses in Multiple Myeloma

September 15th 2021, 8:00pm

Patients with progressed multiple myeloma experienced deep and durble responses through CAR T-cell therapy ciltacabtagene autoleucel therapy.